Identification

Name
Clorazepate
Accession Number
DB00628  (APRD00881)
Type
Small Molecule
Groups
Approved, Illicit
Description

A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions. [PubChem]

Structure
Thumb
Synonyms
  • 7-chloro-2,3-dihydro-2,2-Dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid
  • Clorazepate
  • Clorazepic acid
External IDs
Abbott 35616 / AH 3232 / CB 4306 / Ro 6-6616 / TR 19119
Product Ingredients
IngredientUNIICASInChI Key
Clorazepate dipotassium63FN7G03XY57109-90-7QCHSEDTUUKDTIG-UHFFFAOYSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ClorazepateCapsule15 mgOralAa Pharma Inc1990-12-31Not applicableCanada
ClorazepateCapsule3.75 mgOralAa Pharma Inc1990-12-31Not applicableCanada
ClorazepateCapsule7.5 mgOralAa Pharma Inc1990-12-31Not applicableCanada
Novo-clopate Cap 15mgCapsule15 mgOralNovopharm Limited1984-12-312015-10-26Canada
Novo-clopate Cap 3.75mgCapsule3.75 mgOralNovopharm Limited1984-12-312015-10-26Canada
Novo-clopate Cap 7.5mgCapsule7.5 mgOralNovopharm Limited1984-12-312015-10-26Canada
Tranxene Cap 15mgCapsule15 mgOralAbbott1973-12-312003-08-01Canada
Tranxene Cap 3.75mgCapsule3.75 mgOralAbbott1973-12-312003-08-01Canada
Tranxene Cap 7.5mgCapsule7.5 mgOralAbbott1976-12-312003-08-01Canada
Tranxene T-TabTablet3.75 mg/1OralRecordati Rare Diseases Inc1972-06-232016-10-13Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clorazepate DipotassiumTablet15 mg/1OralMylan Pharmaceuticals1987-07-17Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralRemedy Repack2010-11-182016-10-13Us63304 0553 05 nlmimage10 d015681b
Clorazepate DipotassiumTablet7.5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-07-29Not applicableUs
Clorazepate DipotassiumTablet3.75 mg/1Oralbryant ranch prepack2000-04-27Not applicableUs
Clorazepate DipotassiumTablet3.75 mg/1OralAmerincan Health Packaging2014-07-312017-05-31Us51672 4042 02 nlmimage10 d6156b1b
Clorazepate DipotassiumTablet3.75 mg/1OralRemedy Repack2016-07-21Not applicableUs
Clorazepate DipotassiumTablet15 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-04-27Not applicableUs51672 4044 01 nlmimage10 cd1566cb
Clorazepate DipotassiumTablet7.5 mg/1OralMylan Pharmaceuticals1987-07-17Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralContract Pharmacy Services Pa2011-03-29Not applicableUs
Clorazepate dipotassiumTablet7.5 mg/1OralRanbaxy Inc.2005-01-14Not applicableUs
International/Other Brands
Anksen (Sanovel) / Calner (Medipharm) / Cloranxen (Teva) / Clorazepatum (sanofi-aventis) / Clozene (Weidar) / Dipot (Asian) / Flulium (Pharmasant) / Gen-xene (Alra) / Justum (Sandoz) / Manotran (March) / Medipax (Tecnifar) / Mendon (Abbott Japan) / Polizep (Polipharm) / Tencilan (Finadiet) / Trancap (T P Drug) / Transene (sanofi-aventis) / Tranxen (sanofi-aventis) / Tranxène (sanofi-aventis) / Tranxene (Lundbeck) / Tranxilene (sanofi-aventis) / Tranxilium (sanofi-aventis) / Zetran-5 (Masa Lab)
Categories
UNII
D51WO0G0L4
CAS number
23887-31-2
Weight
Average: 314.723
Monoisotopic: 314.045819935
Chemical Formula
C16H11ClN2O3
InChI Key
XDDJGVMJFWAHJX-UHFFFAOYSA-N
InChI
InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
IUPAC Name
7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
SMILES
OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2

Pharmacology

Indication

For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.

Structured Indications
Pharmacodynamics

Clorazepate is a member of the group of drugs called benzodiazepines. Pharmacologically, clorazepate has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. Studies in healthy men have shown that clorazenate has depressant effects on the central nervous system. Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug.

Mechanism of action

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

TargetActionsOrganism
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
UTranslocator protein
agonist
Human
Absorption

Rapidly absorbed following oral administration (bioavailability is 91%).

Volume of distribution
Not Available
Protein binding

The protein binding of nordiazepam in plasma is high (97-98%).

Metabolism

The drug is metabolized in the liver and excreted primarily in the urine. The primary metabolite, nordiazepam, is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.

Route of elimination

The drug is metabolized in the liver and excreted primarily in the urine.

Half life

The serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.

Clearance
Not Available
Toxicity

Oral LD50 in rats is 1320 mg/kg. In monkeys, oral LD50 exceed 1600 mg/kg. Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clorazepate.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AminophyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Clorazepate can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amperozide.Experimental
AprepitantThe serum concentration of Clorazepate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Asenapine.Approved
AtazanavirThe metabolism of Clorazepate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Clorazepate can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Azaperone.Investigational, Vet Approved
AzelastineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benzyl alcohol.Approved
BoceprevirThe metabolism of Clorazepate can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Clorazepate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Clorazepate can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bupivacaine.Approved, Investigational
BuprenorphineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clorazepate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clorazepate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clorazepate.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Clorazepate is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Clorazepate can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Clorazepate can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clorazepate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clorazepate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Clorazepate is combined with Citalopram.Approved
ClarithromycinThe metabolism of Clorazepate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Clorazepate can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clopenthixol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Clorazepate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clozapine.Approved
CobicistatThe metabolism of Clorazepate can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clorazepate.Approved, Illicit
ConivaptanThe serum concentration of Clorazepate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Clorazepate can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Clorazepate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Clorazepate can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Clorazepate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Clorazepate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Clorazepate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Clorazepate can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Clorazepate can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Clorazepate can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doxepin.Approved
DoxycyclineThe metabolism of Clorazepate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Clorazepate is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
DronedaroneThe metabolism of Clorazepate can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Clorazepate is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Clorazepate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Clorazepate can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Clorazepate is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clorazepate.Approved
EthanolClorazepate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Clorazepate can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clorazepate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Clorazepate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Clorazepate can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clorazepate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Clorazepate.Approved
FospropofolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Clorazepate can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clorazepate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneClorazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorazepate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved
IdelalisibThe serum concentration of Clorazepate can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Iloperidone.Approved
ImatinibThe metabolism of Clorazepate can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Clorazepate can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Indiplon.Investigational
IsavuconazoniumThe metabolism of Clorazepate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Isoflurane.Approved, Vet Approved
IsradipineThe metabolism of Clorazepate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Clorazepate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Clorazepate can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Clorazepate can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lofentanil.Illicit
LopinavirThe metabolism of Clorazepate can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clorazepate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lormetazepam.Approved
LovastatinThe metabolism of Clorazepate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clorazepate.Approved
LuliconazoleThe serum concentration of Clorazepate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Clorazepate can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Clorazepate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clorazepate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Metaxalone.Approved
MethadoneClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clorazepate.Approved
MethotrimeprazineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methylphenobarbital.Approved
MetyrosineClorazepate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Clorazepate can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Clorazepate is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Investigational
MirtazapineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Clorazepate can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clorazepate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nalbuphine.Approved
NefazodoneThe metabolism of Clorazepate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Clorazepate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Clorazepate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Clorazepate can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Clorazepate can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clorazepate.Approved, Investigational
OlaparibThe metabolism of Clorazepate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Clorazepate can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Clorazepate is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Clorazepate can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clorazepate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Clorazepate can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paliperidone.Approved
ParaldehydeClorazepate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Clorazepate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved
PerazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clorazepate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Clorazepate is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Clorazepate can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clorazepate.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Clorazepate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleClorazepate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clorazepate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Prilocaine.Approved
PrimidoneThe metabolism of Clorazepate can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clorazepate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Clorazepate is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quetiapine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Clorazepate can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clorazepate.Approved, Investigational
RifabutinThe metabolism of Clorazepate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Clorazepate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Clorazepate can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Clorazepate can be increased when it is combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Romifidine.Vet Approved
RopiniroleClorazepate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ropivacaine.Approved
RotigotineClorazepate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clorazepate.Approved
SaquinavirThe serum concentration of Clorazepate can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clorazepate.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Clorazepate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Clorazepate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Clorazepate can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Clorazepate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Clorazepate can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Clorazepate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sultopride.Experimental
SuvorexantClorazepate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Clorazepate can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Clorazepate can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Clorazepate can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clorazepate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrodotoxin.Investigational
ThalidomideClorazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Clorazepate can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Clorazepate can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clorazepate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Clorazepate is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe metabolism of Clorazepate can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Veralipride.Experimental
VerapamilThe metabolism of Clorazepate can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Clorazepate can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Clorazepate can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zolazepam.Vet Approved
ZolpidemClorazepate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Schmitt, J.; U.S. Patent 3,516,988; June 23, 1970.

General References
  1. Authors unspecified: Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines. Br Med J. 1980 Mar 29;280(6218):910-2. [PubMed:7388368]
  2. McElhatton PR: The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994 Nov-Dec;8(6):461-75. [PubMed:7881198]
External Links
Human Metabolome Database
HMDB14766
KEGG Drug
D00694
KEGG Compound
C06921
PubChem Compound
2809
PubChem Substance
46506595
ChemSpider
2707
ChEBI
3761
ChEMBL
CHEMBL1213252
Therapeutic Targets Database
DAP000240
PharmGKB
PA164749297
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clorazepate
AHFS Codes
  • 28:24.08 — Benzodiazepines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentLymphoma, T-Cell, Cutaneous / Mycosis Fungoides (MF)1
Not AvailableCompletedNot AvailableHealthy Volunteers1

Pharmacoeconomics

Manufacturers
  • Able laboratories inc
  • American therapeutics inc
  • Clonmel healthcare ltd
  • Gd searle llc
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Sandoz inc
  • Usl pharma inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Lundbeck inc
  • Lederle laboratories div american cyanamid co
  • Ranbaxy laboratories ltd
  • Taro pharmaceuticals usa inc
  • Alra laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral15 mg
CapsuleOral3.75 mg
CapsuleOral7.5 mg
TabletOral15 mg/1
TabletOral3.75 mg/1
TabletOral7.5 mg/1
Prices
Unit descriptionCostUnit
Tranxene t-tablet 15 mg5.41USD tablet
Tranxene-T 15 mg tablet5.08USD tablet
Tranxene t-tablet 7.5 mg3.99USD tablet
Tranxene-T 7.5 mg tablet3.6USD tablet
Tranxene t-tablet 3.75 mg3.21USD tablet
Tranxene-T 3.75 mg tablet3.04USD tablet
Clorazepate 15 mg tablet2.17USD tablet
Clorazepate Dipotassium 15 mg tablet1.27USD tablet
Clorazepate Dipotassium 7.5 mg tablet0.93USD tablet
Clorazepate 7.5 mg tablet0.79USD tablet
Clorazepate Dipotassium 3.75 mg tablet0.76USD tablet
Clorazepate 3.75 mg tablet0.73USD tablet
Apo-Clorazepate 15 mg Capsule0.4USD capsule
Apo-Clorazepate 7.5 mg Capsule0.2USD capsule
Apo-Clorazepate 3.75 mg Capsule0.15USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityVery solubleNot Available
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0248 mg/mLALOGPS
logP2.68ALOGPS
logP3.21ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)3.32ChemAxon
pKa (Strongest Basic)-0.64ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.76 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity82.68 m3·mol-1ChemAxon
Polarizability30.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9285
Blood Brain Barrier+0.8373
Caco-2 permeable+0.5909
P-glycoprotein substrateNon-substrate0.5597
P-glycoprotein inhibitor INon-inhibitor0.9328
P-glycoprotein inhibitor IINon-inhibitor0.9386
Renal organic cation transporterNon-inhibitor0.9049
CYP450 2C9 substrateNon-substrate0.7365
CYP450 2D6 substrateNon-substrate0.8745
CYP450 3A4 substrateNon-substrate0.5798
CYP450 1A2 substrateInhibitor0.7086
CYP450 2C9 inhibitorNon-inhibitor0.756
CYP450 2D6 inhibitorNon-inhibitor0.819
CYP450 2C19 inhibitorNon-inhibitor0.7451
CYP450 3A4 inhibitorNon-inhibitor0.8333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8165
Ames testNon AMES toxic0.8311
CarcinogenicityNon-carcinogens0.659
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9282 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9987
hERG inhibition (predictor II)Non-inhibitor0.9207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives / Benzene and substituted derivatives / Aryl chlorides / 1,3-dicarbonyl compounds / Secondary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Carboxylic acids
show 5 more
Substituents
1,4-benzodiazepine / Alpha-amino acid or derivatives / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / 1,3-dicarbonyl compound / Carboxamide group / Ketimine / Lactam
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
1,4-benzodiazepinone (CHEBI:3761)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Positive allosteric modulator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Cholesterol binding
Specific Function
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in l...
Gene Name
TSPO
Uniprot ID
P30536
Uniprot Name
Translocator protein
Molecular Weight
18827.81 Da
References
  1. Park CH, Carboni E, Wood PL, Gee KW: Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996 Jan;16(1):65-70. [PubMed:8787774]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. [PubMed:10668858]
  2. Sachs B, Erdmann S, Al-Masaoudi T, Merk HF: In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20. [PubMed:11251565]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49